Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Preprint
- 23 October 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Abnormal uterine bleeding is a clinically important but often overlooked concern during antithrombotic therapy, particularly in cardiovascular care where anticoagulant and antiplatelet regimens are used. Objective: To describe paired menstrual changes during cardiovascular antithrombotic therapy and to explore documented increased or prolonged bleeding across treatment classes and observed regimens. Methods: This prospective observational paired clinical follow-up study included 50 menstruating women aged 18–55 years with regular menses who received antithrombotic therapy for cardiovascular conditions. Source records specified monthly follow-up and at least 3 months of anticipated treatment. Primary outcomes were paired changes in menstrual-cycle category and menstrual duration; documented increased or prolonged bleeding and variation across observed regimens were secondary exploratory outcomes. Results: Abnormal menstrual-cycle categories increased from 8/50 (16.0%) to 14/50 (28.0%), and prolonged menses increased from 2/49 (4.1%) to 8/49 (16.3%); both exact McNemar P=0.031. Documented increased or prolonged bleeding was recorded in 17/46 evaluable participants (37.0%). Menstrual-related healthcare use or absence was more frequent among those with documented bleeding than among those without it (9/17 vs 4/29; Fisher P = 0.007). The proportion with documented bleeding varied across seven observed regimens (P=0.006) and was highest among rivaroxaban recipients (13/19, 68.4%). Conclusions: Menstrual changes and bleeding-related clinical burden were observed during follow-up in women receiving antithrombotic therapy for cardiovascular conditions. The proportion with documented bleeding varied across observed regimens and was highest among rivaroxaban recipients. Larger prospective studies using standardized menstrual outcome measures are needed to evaluate between-regimen differences.Keywords
All Related Versions
This publication has 17 references indexed in Scilit:
- Rate of abnormal uterine bleeding in women on anticoagulation for venous thromboembolism: systematic review and meta-analysisJournal of Thrombosis and Haemostasis, 2026
- Prevalence of abnormal uterine bleeding and quality of life after venous thromboembolism by oral anticoagulant use: the GENB-OAC StudyResearch and Practice in Thrombosis and Haemostasis, 2025
- Menstrual bleeding-specific quality of life in women on antiplatelet therapyResearch and Practice in Thrombosis and Haemostasis, 2025
- Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trialResearch and Practice in Thrombosis and Haemostasis, 2024
- Effects of antiplatelet therapy on menstrual blood loss in reproductive-aged women: a systematic reviewResearch and Practice in Thrombosis and Haemostasis, 2023
- Descriptive study of the general practitioners’ perception of direct oral anticoagulants and the risk of genital bleeding in women of childbearing ageJMV-Journal de Médecine Vasculaire, 2020
- The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisionsInternational Journal of Gynecology & Obstetrics, 2018
- Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonistsThrombosis Research, 2015
- Platelet Biology and Response to Antiplatelet Therapy in WomenJACC, 2012
- Menstrual problems and contraception in women of reproductive age receiving oral anticoagulationContraception, 2011